Stay updated on Efficacy Safety in Primary IgA Nephropathy Clinical Trial

Sign up to get notified when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision: v3.3.2 replaces v3.2.0 in the page footer. There are no changes to the study data or visible content.
    Difference
    0.1%
    Check dated 2025-11-26T08:20:41.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Removed the site-wide banner about government funding lapses and NIH operating status; core study details and content remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-19T08:39:17.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-10-28T05:11:26.000Z thumbnail image
  5. Check
    63 days ago
    Change Detected
    Summary
    - Added a government funding lapse notice and operating-status guidance, and confirmed the NIH Clinical Center is open with sources. - Version updated from v3.1.0 to v3.2.0.
    Difference
    4%
    Check dated 2025-10-06T15:54:43.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    - Updated version from v3.0.2 to v3.1.0. - No other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T09:53:49.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Updated from v3.0.1 to v3.0.2, indicating a new release. The 'Back to Top' link was removed, with no evident changes to core page content.
    Difference
    0.2%
    Check dated 2025-09-15T00:15:15.000Z thumbnail image

Stay in the know with updates to Efficacy Safety in Primary IgA Nephropathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.